BACKGROUND: The Notch signaling pathway is closely related with human organ development and tumorgenisis. Jagged2 is among the most popular topic in Notch studies currently. Recent studies found its vital role in tumor metastasis in breast cancer; however, its expression profile and its prognostic value in urothelial carcinoma of bladder have not been investigated. METHODS: Immunohistochemistry was used to detect the expression of Jagged2 in 120 bladder urothelial carcinoma. Moreover, the expression of Jagged2 was analyzed by Western blot in 60 bladder urothelial carcinoma and 20 normal epithelial tissues. MTT assay and flow cytometry and transwell assay were used to examine the proliferative and invasive ability of bladder cancer cells with the treatment of GSIXX (the inhibitor of Jagged2). Prognostic value of Jagged2 expression and its correlation with tumor metastasis and recurrence were evaluated, and the proliferative and invasive ability and cell cycle process of the bladder cancer cells were detected as well. RESULTS: There was a significantly higher Jagged2 expressions in bladder urothelial carcinoma and highly invasive bladder T24 cells than those in bladder normal tissues and the superficial bladder BIU-87 cells. Jagged2 expression was positively correlated with histological grade, p T stage, recurrence, and metastasis. With the increasing concentration of GSIXX, we found that not only the cell proliferation and invasion activity decreased significantly, but also the cell cycle was blocked at G2/M stage. CONCLUSIONS: Jagged2 expression status was closely correlated with important histopathologic characteristics (grades and stages) and the recurrence and metastasis of bladder urothelial carcinomas. Furthermore, Jagged2 played an important function on the bladder cancer cells' proliferation by regulating the cancer cell cycle from G1/S to G2/M and probably promoted the invasion and metastasis of bladder cancer.
BACKGROUND: The Notch signaling pathway is closely related with human organ development and tumorgenisis. Jagged2 is among the most popular topic in Notch studies currently. Recent studies found its vital role in tumor metastasis in breast cancer; however, its expression profile and its prognostic value in urothelial carcinoma of bladder have not been investigated. METHODS: Immunohistochemistry was used to detect the expression of Jagged2 in 120 bladder urothelial carcinoma. Moreover, the expression of Jagged2 was analyzed by Western blot in 60 bladder urothelial carcinoma and 20 normal epithelial tissues. MTT assay and flow cytometry and transwell assay were used to examine the proliferative and invasive ability of bladder cancer cells with the treatment of GSIXX (the inhibitor of Jagged2). Prognostic value of Jagged2 expression and its correlation with tumor metastasis and recurrence were evaluated, and the proliferative and invasive ability and cell cycle process of the bladder cancer cells were detected as well. RESULTS: There was a significantly higher Jagged2 expressions in bladder urothelial carcinoma and highly invasive bladder T24 cells than those in bladder normal tissues and the superficial bladder BIU-87 cells. Jagged2 expression was positively correlated with histological grade, p T stage, recurrence, and metastasis. With the increasing concentration of GSIXX, we found that not only the cell proliferation and invasion activity decreased significantly, but also the cell cycle was blocked at G2/M stage. CONCLUSIONS:Jagged2 expression status was closely correlated with important histopathologic characteristics (grades and stages) and the recurrence and metastasis of bladder urothelial carcinomas. Furthermore, Jagged2 played an important function on the bladder cancer cells' proliferation by regulating the cancer cell cycle from G1/S to G2/M and probably promoted the invasion and metastasis of bladder cancer.
Authors: He Zhu; Feriyl Bhaijee; Nivin Ishaq; Dominique J Pepper; Kandis Backus; Alexandra S Brown; Xinchun Zhou; Lucio Miele Journal: Am J Cancer Res Date: 2013-04-03 Impact factor: 6.166
Authors: Laura Asnaghi; James T Handa; Shannath L Merbs; J William Harbour; Charles G Eberhart Journal: Invest Ophthalmol Vis Sci Date: 2013-01-09 Impact factor: 4.799
Authors: Antonio Maraver; Pablo J Fernandez-Marcos; Timothy P Cash; Marinela Mendez-Pertuz; Marta Dueñas; Paolo Maietta; Paola Martinelli; Maribel Muñoz-Martin; Mónica Martínez-Fernández; Marta Cañamero; Giovanna Roncador; Jorge L Martinez-Torrecuadrada; Dimitrios Grivas; Jose Luis de la Pompa; Alfonso Valencia; Jesús M Paramio; Francisco X Real; Manuel Serrano Journal: J Clin Invest Date: 2015-01-09 Impact factor: 14.808
Authors: Aleksandra M Dudek; Sita H Vermeulen; Dimitar Kolev; Anne J Grotenhuis; Lambertus A L M Kiemeney; Gerald W Verhaegh Journal: Cell Oncol (Dordr) Date: 2018-06-28 Impact factor: 6.730
Authors: Gerald B Schulz; Sefer Elezkurtaj; Teresa Börding; Eva Marina Schmidt; Manal Elmasry; Christian G Stief; Thomas Kirchner; Alexander Karl; David Horst Journal: Cancer Sci Date: 2021-03-31 Impact factor: 6.716